Free Trial

Cryo-Cell International Q3 2024 Earnings Report

Cryo-Cell International logo
$6.44 +0.07 (+1.10%)
As of 04:10 PM Eastern

Cryo-Cell International EPS Results

Actual EPS
$0.13
Consensus EPS
$0.02
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Cryo-Cell International Revenue Results

Actual Revenue
$8.07 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cryo-Cell International Announcement Details

Quarter
Q3 2024
Time
TAS

Conference Call Resources

Remove Ads

Cryo-Cell International Earnings Headlines

Cryo-Cell price target lowered to $8.50 from $9 at Maxim
Cryo-Cell reports FY24 EPS 5c vs ($1.14) last year
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
CRYO-CELL International, Inc. trading resumes
See More Cryo-Cell International Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cryo-Cell International? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cryo-Cell International and other key companies, straight to your email.

About Cryo-Cell International

Cryo-Cell International (NYSEAMERICAN:CCEL) engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

View Cryo-Cell International Profile

More Earnings Resources from MarketBeat